ARS Pharmaceuticals, Inc.
SPRYFigures shown here come from public SEC filings. Dates beside each section show the available history.
How ARS Pharmaceuticals, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 26, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Tannin Capital LLC | 2026-03-31 | 18,593 | $149K | SEC filing |
| ALPS ADVISORS INC | 2026-03-31 | 80,830 | $649K | SEC filing |
| Corient Private Wealth LLC | 2026-03-31 | 80,943 | $650K | SEC filing |
| Bernard Wealth Management Corp. | 2026-03-31 | 2,520 | $20.2K | SEC filing |
| Norman Fields, Gottscho Capital Management, LLC | 2026-03-31 | 39,850 | $320K | SEC filing |
| Sterling Capital Management LLC | 2026-03-31 | 383 | $3.08K | SEC filing |
| OSAIC HOLDINGS, INC. | 2026-03-31 | 3,692 | $29.6K | SEC filing |
| Kestra Advisory Services, LLC | 2026-03-31 | 40,920 | $329K | SEC filing |
| BESSEMER GROUP INC | 2026-03-31 | 7,525 | Not shown | SEC filing |
| Private Advisor Group, LLC | 2026-03-31 | 30,242 | $243K | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 316,673 | $2.54M | SEC filing |
| LEVIN CAPITAL STRATEGIES, L.P. | 2026-03-31 | 552,561 | $4.44M | SEC filing |
| Pinnacle Wealth Planning Services, Inc. | 2026-03-31 | 17 | $137 | SEC filing |
| OPPENHEIMER & CO INC | 2026-03-31 | 12,439 | $99.9K | SEC filing |
| Legal & General Group Plc | 2026-03-31 | 47,885 | $385K | SEC filing |
| JONES FINANCIAL COMPANIES LLLP | 2026-03-31 | 11,142 | $89.9K | SEC filing |
| Rubric Capital Management LP | 2026-03-31 | 8,000,000 | $64.2M | SEC filing |
| NEW YORK STATE COMMON RETIREMENT FUND | 2026-03-31 | 17,707 | $142K | SEC filing |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 2026-03-31 | 31,568 | $253K | SEC filing |
| Hilton Head Capital Partners, LLC | 2026-03-31 | 365 | $2.93K | SEC filing |
- Each value is checked against ARS Pharmaceuticals, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at ARS Pharmaceuticals, Inc.'s share price.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among ARS Pharmaceuticals, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-11-12 · Chakma Justin: Larger than 102 of the 106 other insider sales of Common Stock on file. SEC filing
- 2025-05-20 · SAUNDERS BRENT L: Larger than 101 of the 106 other insider sales of Common Stock on file. SEC filing
- 2025-05-20 · Fitzpatrick Alexander A: Larger than 99 of the 106 other insider sales of Common Stock on file. SEC filing
- 2024-12-12 · Chakma Justin: Larger than 100 of the 106 other insider sales of Common Stock on file. SEC filing
- 2024-12-03 · Shawver Laura: Larger than 97 of the 106 other insider sales of Common Stock on file. SEC filing
- 2024-12-02 · Shawver Laura: Larger than 98 of the 106 other insider sales of Common Stock on file. SEC filing
- 2024-08-22 · ORBIMED ADVISORS LLC: Larger than 103 of the 106 other insider sales of Common Stock on file. SEC filing
- 2024-08-22 · Thompson Peter A.: Larger than 103 of the 106 other insider sales of Common Stock on file. SEC filing
- 2024-08-21 · Thompson Peter A.: Larger than 105 of the 106 other insider sales of Common Stock on file. SEC filing
- 2024-08-21 · ORBIMED ADVISORS LLC: Larger than 105 of the 106 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-12 | Karas Eric · Chief Commercial Officer | Common Stock | S — Open market or private sale | −25,000 | 10.00 | SEC filing |
| 2026-06-12 | Fitzpatrick Alexander A · Chief Legal Officer | Common Stock | S — Open market or private sale | −3,355 | 10.00 | SEC filing |
| 2025-11-13 | Dorsey Brian · Chief Operating Officer | Common Stock | S — Open market or private sale | −21,828 | 8.71 | SEC filing |
| 2025-11-12 | Chakma Justin · Chief Business Officer | Common Stock | S — Open market or private sale | −30,000 | 8.91 | SEC filing |
| 2025-11-12 | Chakma Justin · Chief Business Officer | Common Stock | S — Open market or private sale | −136,380 | 8.86 | SEC filing |
| 2025-08-21 | Scott Kathleen D. · Chief Financial Officer | Common Stock | S — Open market or private sale | −12,500 | 15.00 | SEC filing |
| 2025-08-21 | Lowenthal Richard E · PRESIDENT AND CEO | Common Stock | S — Open market or private sale | −50,000 | 14.49 | SEC filing |
| 2025-08-20 | Tanimoto Sarina · CHIEF MEDICAL OFFICER | Common Stock | S — Open market or private sale | −37,656 | 14.09 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-24 | Dadoo Rajeev · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +30,000 | SEC filing |
| 2026-06-24 | Islam Saqib · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +30,000 | SEC filing |
| 2026-06-24 | Kelly Michael · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +30,000 | SEC filing |
| 2026-06-24 | RA Capital Healthcare Fund LP · Director, 10% owner | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +30,000 | SEC filing |
| 2026-06-24 | Thompson Peter A. · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +30,000 | SEC filing |
| 2026-06-24 | SCHNEIDER PHILLIP M · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +30,000 | SEC filing |
| 2026-06-24 | Shah Pratik · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +30,000 | SEC filing |
| 2026-06-24 | SAUNDERS BRENT L · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +30,000 | SEC filing |
Showing 8 of 22 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.